BASO II: a randomised trial for the management of small well-differentiated and special type carcinomas of the breast

Scottish Cancer Therapy Network (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新: 2020年3月3日

适应症

试验速览

2007 results in Blamey RW, Chetty U, Bates T. Radiotherapy and/or tamoxifen after conserving surgery for breast cancers of excellent prognosis: BASO II TRIAL. Eur J Cancer Suppl. 2007;5 O-11.

•1. Aged <70 years
•2. Unilateral invasive breast carcinoma grade I or of a special type:
•b. Tubular/cribriform
•c. Cribriform
•d. Papillary
•f. Not lobular, medullary or other rarer special types of breast carcinoma
•3. Tumour size <2 cm
•4. No evidence of vascular invasion
•5. The histological examination of at least one lymph node is required. There should be no evidence of metastases
•6. No distant metastases
•7. No other systemic disease
•8. No previous invasive malignant disease, except basal cell carcinoma of the skin adequately treated or adequately treated in situ carcinoma of the cervix

•Patients with bilateral breast cancer, Paget's disease of the nipple, in situ carcinoma only or tumours which are essentially ductal carcinoma in situ but with microinvasion are to be excluded.

发起方

Scottish Cancer Therapy Network (UK)